BACKGROUND: The availability of suitable lung donors has remained a significant barrier to lung transplantation. The clinical relevance of an isolated positive Gram stain in potential donor lungs, which occurs in >80%, is unclear. Low doses of lipopolysaccharide (LPS) have been protective in several models of ischemia-reperfusion injury through a pre-conditioning response. We sought to demonstrate that low-dose LPS is protective against subsequent lung ischemia-reperfusion injury. METHODS: Pathogen-free Long-Evans rats were pre-treated with vehicle or LPS 24 hours before 90 minutes of ischemia and up to 4 hours of reperfusion. Lungs were assessed for vascular permeability, myeloperoxidase content, bronchoalveolar lavage inflammatory cell and cytokine/chemokine content, as well as nuclear translocation of nuclear factor kappaB (NFkappaB) and activator protein-1 (AP-1), and interleukin-1 receptor-associated kinase-1 (IRAK-1) and stress-activated protein kinase (SAPK) activation. RESULTS: Compared with positive controls, LPS pre-treatment resulted in reductions in vascular permeability (70%, p < 0.001), myeloperoxidase content (93%, p < 0.001), bronchoalveolar lavage inflammatory cells (91%, p < 0.001), and inflammatory cytokine/chemokine content (cytokine-induced neutrophil chemoattractant, 99%, p = 0.003; interleukin-1beta, 72%, p < 0.0001; tumor necrosis factor-alpha, 76%, p < 0.0001), NFkappaB (86%, p < 0.001) and AP-1 (97%, p < 0.001) nuclear translocation, and IRAK-1 (87%, p < 0.001) and SAPK (80%, p < 0.001) phosphorylation. CONCLUSIONS: Lipopolysaccharide pre-treatment reduced lung injury and inflammatory mediator production after subsequent exposure to ischemia-reperfusion. Understanding the clinical significance of lipopolysaccharide in donor lungs has the potential to expand and clarify donor inclusion criteria.
BACKGROUND: The availability of suitable lung donors has remained a significant barrier to lung transplantation. The clinical relevance of an isolated positive Gram stain in potential donor lungs, which occurs in >80%, is unclear. Low doses of lipopolysaccharide (LPS) have been protective in several models of ischemia-reperfusion injury through a pre-conditioning response. We sought to demonstrate that low-dose LPS is protective against subsequent lung ischemia-reperfusion injury. METHODS: Pathogen-free Long-Evans rats were pre-treated with vehicle or LPS 24 hours before 90 minutes of ischemia and up to 4 hours of reperfusion. Lungs were assessed for vascular permeability, myeloperoxidase content, bronchoalveolar lavage inflammatory cell and cytokine/chemokine content, as well as nuclear translocation of nuclear factor kappaB (NFkappaB) and activator protein-1 (AP-1), and interleukin-1 receptor-associated kinase-1 (IRAK-1) and stress-activated protein kinase (SAPK) activation. RESULTS: Compared with positive controls, LPS pre-treatment resulted in reductions in vascular permeability (70%, p < 0.001), myeloperoxidase content (93%, p < 0.001), bronchoalveolar lavage inflammatory cells (91%, p < 0.001), and inflammatory cytokine/chemokine content (cytokine-induced neutrophil chemoattractant, 99%, p = 0.003; interleukin-1beta, 72%, p < 0.0001; tumor necrosis factor-alpha, 76%, p < 0.0001), NFkappaB (86%, p < 0.001) and AP-1 (97%, p < 0.001) nuclear translocation, and IRAK-1 (87%, p < 0.001) and SAPK (80%, p < 0.001) phosphorylation. CONCLUSIONS:Lipopolysaccharide pre-treatment reduced lung injury and inflammatory mediator production after subsequent exposure to ischemia-reperfusion. Understanding the clinical significance of lipopolysaccharide in donor lungs has the potential to expand and clarify donor inclusion criteria.
Authors: M Zenati; R D Dowling; J S Dummer; I L Paradis; V C Arena; J M Armitage; R L Kormos; R L Hardesty; B P Griffith Journal: J Heart Transplant Date: 1990 Sep-Oct
Authors: H P van Helden; W C Kuijpers; D Steenvoorden; C Go; P L Bruijnzeel; M van Eijk; H P Haagsman Journal: Exp Lung Res Date: 1997 Jul-Aug Impact factor: 2.459
Authors: Sanjay Sethi; Jane Maloney; Lori Grove; Catherine Wrona; Charles S Berenson Journal: Am J Respir Crit Care Med Date: 2006-02-10 Impact factor: 21.405
Authors: Jose M Prince; Ryan M Levy; Runkuan Yang; Kevin P Mollen; Mitchell P Fink; Yoram Vodovotz; Timothy R Billiar Journal: J Am Coll Surg Date: 2006-01-18 Impact factor: 6.113
Authors: A Harjula; J C Baldwin; V A Starnes; E B Stinson; P E Oyer; S W Jamieson; N E Shumway Journal: J Thorac Cardiovasc Surg Date: 1987-12 Impact factor: 5.209
Authors: Byung Soo Kim; Sun Woo Lim; Can Li; Jung Shim Kim; Bo Kyung Sun; Kyung Ohk Ahn; Sang Woo Han; Jin Kim; Chul Woo Yang Journal: Transplantation Date: 2005-05-27 Impact factor: 4.939
Authors: Holly L Rosenzweig; Nikola S Lessov; David C Henshall; Manabu Minami; Roger P Simon; Mary P Stenzel-Poore Journal: Stroke Date: 2004-09-16 Impact factor: 7.914
Authors: Don Hayes; Benjamin T Kopp; Stephen E Kirkby; Susan D Reynolds; Heidi M Mansour; Joseph D Tobias; Dmitry Tumin Journal: Lung Date: 2016-06-08 Impact factor: 2.584
Authors: Regina Sordi; Fausto Chiazza; Nimesh S A Patel; Rachel A Doyle; Massimo Collino; Christoph Thiemermann Journal: PLoS One Date: 2015-04-01 Impact factor: 3.240
Authors: Ryan C Turner; Zachary J Naser; Brandon P Lucke-Wold; Aric F Logsdon; Reyna L Vangilder; Rae R Matsumoto; Jason D Huber; Charles L Rosen Journal: Neuroimmunol Neuroinflamm Date: 2017-01-20
Authors: Steven S C Cho; Ina Rudloff; Philip J Berger; Michael G Irwin; Marcel F Nold; Wei Cheng; Claudia A Nold-Petry Journal: BMC Gastroenterol Date: 2013-04-22 Impact factor: 3.067